Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,204 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,204 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total value of $305,900.28. Following the sale, the insider directly owned 132,429 shares in the company, valued at approximately $33,646,236.03. This represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.

Natera Stock Performance

Shares of Natera stock traded up $1.60 on Wednesday, hitting $253.82. 925,147 shares of the company traded hands, compared to its average volume of 1,091,572. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The business has a 50-day simple moving average of $244.16 and a 200 day simple moving average of $221.65. The stock has a market capitalization of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51.

Analyst Ratings Changes

A number of analysts have issued reports on NTRA shares. Barclays reduced their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, June 24th. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. The Goldman Sachs Group started coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price on the stock. Guggenheim boosted their target price on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Canaccord Genuity Group increased their price target on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently bought and sold shares of NTRA. Family Wealth Partners LLC bought a new position in Natera during the second quarter valued at $210,000. Handelsbanken Fonder AB grew its stake in shares of Natera by 29.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 207,800 shares of the medical research company’s stock worth $56,407,000 after buying an additional 46,800 shares in the last quarter. Everhart Financial Group Inc. bought a new stake in shares of Natera in the 2nd quarter worth about $254,000. Teamwork Financial Advisors LLC bought a new stake in shares of Natera in the 2nd quarter worth about $2,936,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Natera during the 2nd quarter valued at about $59,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.